Disease · HP_0004757
Paroxysmal atrial fibrillation
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Paroxysmal atrial fibrillation. Diseases, record HP_0004757. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0004757
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Paroxysmal atrial fibrillation
- Open Targets ID
- HP_0004757
- Other names
- Atrial fibrillation, paroxysmal, Intermittent atrial fibrillation, Paroxysmal AF
- Highest stage of its drugs
- Phase 3, for 1 of its 10 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DABIGATRAN | CHEMBL48361 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RANOLAZINE | CHEMBL1404 | Small molecule | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
| ADENOSINE | CHEMBL477 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DRONEDARONE | CHEMBL184412 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLECAINIDE | CHEMBL652 | Small molecule | Phase 1 | TTD | 1 | 0 | 0 | Drugs and targets |
| OXYTOCIN | CHEMBL395429 | Protein | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| APIXABAN | CHEMBL231779 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EDOXABAN | CHEMBL1269025 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVAROXABAN | CHEMBL198362 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets24
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| F10 | Coagulation factor X | 3 | Coagulation factor X inhibitor | Unknown | https://conductscience.org/library/genes/2159 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor agonist | Phase 2 | https://conductscience.org/library/genes/140 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/778 | Drugs and targets |
1 to 10 of 24
See all 24 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01522651 | Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation | Phase 2 | 134 | 2020-11-06 | Atrial Fibrillation | DRONEDARONE, RANOLAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT03032965 | Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation | Phase 2 | 131 | 2017-12-13 | Atrial Fibrillation | ADENOSINE | Its record names the disease | ClinicalTrials.gov |
| NCT01780337 | Oxytocin Effects on Cardiac Electrophysiology | Early phase 1 | 12 | 2016-06-17 | Cardiac Arrhythmia | OXYTOCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02313584 | Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk | Phase 3 | 464 | Atrial Fibrillation, Thromboembolism | DABIGATRAN | Its record names the disease | ClinicalTrials.gov | |
| NCT04151680 | Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients | 100 | Ischemic Heart Disease, Atrial Fibrillation | APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN | Its record names the disease | ClinicalTrials.gov | ||
| NCT07482020 | SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism | Phase 2 | 66 | Atrial Fibrillation (AF), Hypertension | EMPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Cardiac Perforation | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Pulmonary Vein Stenosis | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Number of Subjects Who Need Repeat Ablations | 12 of 61 | 9 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Death | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Stroke | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: deaths from any cause | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Incidence of Atrio-esophageal Fistula | 0 of 61 | 0 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: Freedom From Any Atrial Arrhythmias | 24 of 61 | 23 of 68 | 129 | NCT03032965 | Trial comparisons |
| Adenosine and Isoproterenol vs Isoproterenol: serious adverse events | 4 of 61 | 3 of 68 | 129 | NCT03032965 | Trial comparisons |
| Oxytocin vs Saline: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT01780337 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 26226999 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0004757
GET https://conductscience.org/api/diseases/v1/HP_0004757/targets?page=2